COR vs HSIC
Cencora and Henry Schein, both Healthcare
Cencora is the larger company at $62B against $9.4B. On trailing earnings COR is the cheaper of the two at a P/E of 24.1 against 24.6, a gap that is only a bargain if the two are growing at similar rates. Over the past year HSIC returned +24% against +13% for COR. The RyuScore puts COR ahead, 64 against 61 out of 100.
| Figure | COR | HSIC |
|---|---|---|
| Last close | $325 | $84.26 |
| Market cap | $62B | $9.4B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 24.1 | 24.6 |
| Dividend yield | 0.7% | n/a |
| 1-year return | +13% | +24% |
| 5-year return | +183% | +7.4% |
| RyuScoresector-relative, 1–10 | 64/100 | 61/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Cencora
Revenue of $85B in Q3 2026, net income $764M. Its largest reported line is US Healthcare Solutions, 92% of the disclosed total.
Henry Schein
Revenue of $3.5B in Q2 2026, net income $94M. Its largest reported line is Global Distribution And Value Added Services, 69% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.